Applied Therapeutics, Inc. (APLT)

NASDAQ: APLT · IEX Real-Time Price · USD
0.845
+0.085 (11.22%)
Jun 24, 2022 4:00 PM EDT - Market closed

Company Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.

Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.

The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy.

Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia.

Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics, Inc.
Applied Therapeutics Logo
Country United States
Founded 2016
IPO Date May 14, 2019
Industry Biotechnology
Sector Health Care
Employees 33

Contact Details

Address:
545 5Th Avenue, Suite 1400
New York, New York 10017
United States
Phone 212 220 9226
Website appliedtherapeutics.com

Stock Details

Ticker Symbol APLT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $10.00
CIK Code 1697532

Key Executives

Name Position
Dr. Shoshana Shendelman Ph.D. Chair of the Board of Directors, Founder, President, Chief Executive Officer and Secretary
Dr. Riccardo Perfetti M.D., Ph.D. Chief Medical Officer
Chids Mahadevan Senior Vice President of Finance and Interim Principal Financial Officer
Steven Ortega Chief Accounting Officer
Adam Hansard Chief Commercial Officer

Latest SEC Filings

Date Type Title
Jun 22, 2022 424B5 Prospectus [Rule 424(b)(5)]
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
Jun 7, 2022 4 Statement of changes in beneficial ownership of securities
Jun 3, 2022 8-K Current report
May 18, 2022 4 Statement of changes in beneficial ownership of securities
May 12, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 12, 2022 8-K Current report